文献速递肺血管病与心包/心肌炎瓣膜病与结构性心脏病

马西替坦治疗艾森曼格综合征的评估

Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
PubMed 文献 · Circulation · 2019-01-01

MAESTRO研究为多中心、双盲、随机、安慰剂对照的16周III期试验,评估内皮素受体拮抗剂马西替坦在艾森曼格综合征患者中的疗效与安全性。95%CL -22.8, 13.5;P=0.612)。马西替坦未在运动能力上优于安慰剂,但NT-proBNP下降,PVRi有降低趋势。

要点

  • 马西替坦10 mg每日一次治疗16周未改善艾森曼格综合征患者6分钟步行距离。
  • 马西替坦组NT-proBNP较安慰剂组下降(几何均值比0.80;95%CL 0.68, 0.94)。
  • 马西替坦组血红蛋白较基线下降≥2 g/dL的发生率高于安慰剂组(36.0% vs 8.9%)。

核心结论

  • 马西替坦在艾森曼格综合征患者中未在主要终点(6分钟步行距离变化)上优于安慰剂。

研究设计与样本

  • 多中心、双盲、随机、安慰剂对照的16周III期MAESTRO研究。
  • 纳入年龄≥12岁、WHO功能分级II-III级的艾森曼格综合征患者,按1:1随机接受安慰剂或马西替坦10 mg每日一次。

主要发现

  • 第16周时6分钟步行距离较基线的平均变化在马西替坦组和安慰剂组分别为18.3 m和19.7 m(最小二乘均值差-4.7 m;95%CL -22.8, 13.5;P=0.612)。
  • WHO功能分级从基线至第16周改善的患者比例在马西替坦组和安慰剂组分别为8.8%和14.3%(比值比0.53;95%CL 0.23, 1.24)。
  • NT-proBNP水平马西替坦组较安慰剂组下降(几何均值比0.80;95%CL 0.68, 0.94)。
  • 血流动力学亚组(n=39)中,马西替坦组PVRi较安慰剂组下降(几何均值比0.87;95%CL 0.73, 1.03)。
  • 马西替坦组较安慰剂组常见不良事件为头痛(11.4% vs 4.5%)和上呼吸道感染(9.6% vs 6.3%);血红蛋白较基线下降≥2 g/dL的发生率分别为36.0%和8.9%。

临床怎么用

  • 马西替坦未改善艾森曼格综合征患者的运动能力,不推荐以改善6分钟步行距离为目的使用。
  • 使用马西替坦时需监测血红蛋白下降等不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Eisenmenger syndrome describes congenital heart disease-associated severe pulmonary hypertension accompanied by right-to-left shunting. The multicenter, double-blind, randomized, placebo-controlled, 16-week, phase III MAESTRO study (Macitentan in Eisenmenger Syndrome to Restore Exercise Capacity) evaluated the efficacy and safety of the endothelin receptor antagonist macitentan in patients with Eisenmenger syndrome. METHODS: Patients with Eisenmenger syndrome aged ≥12 years and in World Health Organization functional class II-III were randomized 1:1 to placebo or macitentan 10 mg once daily for 16 weeks. Patients with complex cardiac defects, Down syndrome and background PAH therapy were eligible. The primary end point was change from baseline to week 16 in 6-minute walk distance. Secondary end points included change from baseline to week 16 in World Health Organization functional class. Exploratory end points included NT-proBNP (N-terminal pro-B-type natriuretic peptide) at end of treatment expressed as a percentage of baseline. In a hemodynamic substudy, exploratory end points included pulmonary vascular resistance index (PVRi) at week 16 as a percentage of baseline. RESULTS: Two hundred twenty six patients (macitentan n=114; placebo n=112) were randomized. At baseline, 60% of patients were in World Health Organization functional class II and 27% were receiving phosphodiesterase type-5 inhibitors. At week 16, the mean change from baseline in 6-minute walk distance was 18.3 m and 19.7 m in the macitentan and placebo groups (least-squares mean difference, -4.7 m; 95% confidence limit (CL), -22.8, 13.5; P=0.612). World Health Organization functional class improved from baseline to week 16 in 8.8% and 14.3% of patients in the macitentan and placebo groups (odds ratio, 0.53; 95% CL, 0.23, 1.24). NT-proBNP levels decreased with macitentan versus placebo (ratio of geometric means, 0.80; 95% CL, 0.68, 0.94). In the hemodynamic substudy (n=39 patients), macitentan decreased PVRi compared with placebo (ratio of geometric means, 0.87; 95% CL, 0.73, 1.03). The most common adverse events with macitentan versus placebo were headache (11.4 versus 4.5%) and upper respiratory tract infection (9.6 versus 6.3%); a hemoglobin decrease from baseline of ≥2 g/dL occurred in 36.0% versus 8.9% of patients. Five patients (3 macitentan; 2 placebo) prematurely discontinued treatment and 1 patient died (macitentan group). CONCLUSIONS: Macitentan did not show superiority over placebo on the primary end point of change from baseline to week 16 in exercise capacity in patients with Eisenmenger syndrome. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01743001.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Gatzoulis MA, Landzberg M, Beghetti M, et al. Evaluation of Macitentan in Patients With Eisenmenger Syndrome. Circulation. 2019. PMID: 30586694. doi:10.1161/CIRCULATIONAHA.118.033575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。